HK1036618A1 - Quinoline derivatives - Google Patents
Quinoline derivativesInfo
- Publication number
- HK1036618A1 HK1036618A1 HK01105489A HK01105489A HK1036618A1 HK 1036618 A1 HK1036618 A1 HK 1036618A1 HK 01105489 A HK01105489 A HK 01105489A HK 01105489 A HK01105489 A HK 01105489A HK 1036618 A1 HK1036618 A1 HK 1036618A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- quinoline derivatives
- quinoline
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9801474A SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Quinoline Derivatives |
PCT/SE1999/000676 WO1999055678A1 (fr) | 1998-04-27 | 1999-04-26 | Derives de quinoline |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1036618A1 true HK1036618A1 (en) | 2002-01-11 |
Family
ID=20411103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK01105489A HK1036618A1 (en) | 1998-04-27 | 2001-08-07 | Quinoline derivatives |
Country Status (33)
Country | Link |
---|---|
EP (1) | EP1073639B1 (fr) |
JP (1) | JP4045069B2 (fr) |
KR (1) | KR100571534B1 (fr) |
CN (1) | CN1113057C (fr) |
AP (1) | AP1293A (fr) |
AT (1) | ATE228505T1 (fr) |
AU (1) | AU747550B2 (fr) |
BR (1) | BR9909925B1 (fr) |
CA (1) | CA2329788C (fr) |
CZ (1) | CZ297439B6 (fr) |
DE (1) | DE69904162T2 (fr) |
DK (1) | DK1073639T3 (fr) |
EE (1) | EE04275B1 (fr) |
ES (1) | ES2188242T3 (fr) |
HK (1) | HK1036618A1 (fr) |
HR (1) | HRP20000726B1 (fr) |
HU (1) | HU227709B1 (fr) |
ID (1) | ID26277A (fr) |
IL (2) | IL138160A0 (fr) |
IS (1) | IS2082B (fr) |
ME (1) | ME00870B (fr) |
NO (1) | NO315606B1 (fr) |
NZ (1) | NZ506641A (fr) |
OA (1) | OA11547A (fr) |
PL (1) | PL190441B1 (fr) |
PT (1) | PT1073639E (fr) |
RS (1) | RS50029B (fr) |
RU (1) | RU2197481C2 (fr) |
SE (1) | SE9801474D0 (fr) |
TR (1) | TR200003061T2 (fr) |
UA (1) | UA60354C2 (fr) |
WO (1) | WO1999055678A1 (fr) |
ZA (1) | ZA200004601B (fr) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0002320D0 (sv) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
SE0201778D0 (sv) * | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
KR100908655B1 (ko) | 2002-11-27 | 2009-07-21 | 엘지디스플레이 주식회사 | 데이터 공급시간의 변조방법과 이를 이용한액정표시장치의 구동방법 및 장치 |
SE0400235D0 (sv) * | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
SE0401578D0 (sv) * | 2004-06-18 | 2004-06-18 | Active Biotech Ab | Novel compounds |
US7838522B2 (en) | 2004-11-17 | 2010-11-23 | Ares Trading S.A. | Benzothiazole formulations and use thereof |
EP1828160B1 (fr) | 2004-12-21 | 2011-12-14 | Merck Serono SA | Derivés cycliques sulfonylamino utiles comme des inhibiteurs de mmp |
JP4950070B2 (ja) | 2005-01-31 | 2012-06-13 | メルク セローノ ソシエテ アノニム | N−ヒドロキシアミド誘導体及びその使用 |
BRPI0613042A2 (pt) | 2005-07-15 | 2010-12-14 | Serono Lab | inibidores de jnk para o tratamento de endometriose |
KR20080044836A (ko) | 2005-07-15 | 2008-05-21 | 라보라뚜와르 세로노 에스. 에이. | 자궁내막증 치료용 jnk 억제제 |
AU2006286489B2 (en) | 2005-09-01 | 2012-08-09 | Ares Trading S.A. | Treatment of optic neuritis |
CA2625287C (fr) | 2005-10-19 | 2016-07-26 | Teva Pharmaceutical Industries Ltd. | Cristaux de sodium de laquinimod, et procede de fabrication de ceux-ci |
ZA200810790B (en) * | 2006-06-12 | 2010-03-31 | Teva Pharma | Stable laquinimod preparations |
EP2234485B1 (fr) | 2007-12-20 | 2013-11-13 | Teva Pharmaceutical Industries, Ltd. | Préparations de laquinimod stables |
KR20160079147A (ko) * | 2008-09-03 | 2016-07-05 | 테바 파마슈티컬 인더스트리즈 리미티드 | 면역 기능을 지닌 2―옥소―1,2―다이하이드로―퀴놀린 조절제 |
MX2012001333A (es) * | 2009-07-30 | 2012-06-01 | Teva Pharma | Tratamiento de la enfermedad de crohn con la laquinimod. |
ES2586843T3 (es) | 2009-08-10 | 2016-10-19 | Teva Pharmaceutical Industries Ltd. | Tratamiento de trastornos relacionados con BDNF usando laquinimod |
PL2542080T3 (pl) * | 2010-03-03 | 2017-02-28 | Teva Pharmaceutical Industries Ltd. | Leczenie toczniowego zapalenia stawów z zastosowaniem lakwinimodu |
SI2542079T1 (sl) * | 2010-03-03 | 2014-08-29 | Teva Pharmaceutical Industries Ltd. | Zdravljenje revmatoidnega artritisa s kombinacijo lakvinimoda in metotreksata |
AU2011223692A1 (en) * | 2010-03-03 | 2012-10-25 | Teva Pharmaceutical Industries Ltd. | Treatment of lupus nephritis using laquinimod |
WO2011116091A1 (fr) | 2010-03-17 | 2011-09-22 | Novartis Ag | Distributeur |
EA025377B1 (ru) | 2010-07-09 | 2016-12-30 | Тева Фармасьютикал Индастриз Лтд. | Дейтерированный n-этил-n-фенил-1,2-дигидро-4-гидрокси-5-хлор-1-метил-2-оксохинолин-3-карбоксамид, его соли и их применение |
MX2013000332A (es) * | 2010-07-09 | 2013-02-26 | Teva Pharma | 5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-dihidroquinolina-3-ca rboxamida, sales y usos de la misma. |
PL2590949T3 (pl) * | 2010-07-09 | 2016-06-30 | Active Biotech Ab | Sposób wytwarzania chinolino-3-karboksyamidów |
EP2444086A1 (fr) | 2010-10-22 | 2012-04-25 | Almirall, S.A. | Combinaisons comportant des inhibiteurs de DHODH et de COX |
MX2014004420A (es) | 2011-10-12 | 2014-07-09 | Teva Pharma | Tratamiento de esclerosis multiple con combinacion de laquinimod y fingolimod. |
AR089862A1 (es) * | 2012-02-03 | 2014-09-24 | Teva Pharma | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA |
JP6215238B2 (ja) | 2012-02-16 | 2017-10-18 | テバ ファーマシューティカル インダストリーズ リミティド | N−エチル−n−フェニル−1,2−ジヒドロ−4,5−ジ−ヒドロキシ−1−メチル−2−オキソ−3−キノリンカルボキサミド、その製剤、および使用 |
TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | N-乙基-4-羥基-1-甲基-5-(甲基(2,3,4,5,6-五羥基己基)胺基)-2-側氧-n-苯基-1,2-二氫喹啉-3-甲醯胺 |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
KR20150091077A (ko) | 2012-11-07 | 2015-08-07 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드의 아민염 |
RU2545056C2 (ru) * | 2012-12-10 | 2015-03-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здавоохранения и социального развития Российской Федерации (ГБОУ ВПО ПГФА Минздравсоцразвития России) | Противовоспалительное и анальгетическое средство на основе изопропиламида 1,2-дигидро-1н-2-оксоцинхониновой кислоты |
SG11201505818WA (en) * | 2013-02-15 | 2015-08-28 | Teva Pharma | Treatment of multiple sclerosis with laquinimod |
AU2014236232A1 (en) | 2013-03-14 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
AU2015253330A1 (en) | 2014-04-29 | 2016-12-01 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status |
CA2961978C (fr) | 2014-09-23 | 2023-03-14 | Active Biotech Ab | Quinoleine carboxamides destinees a etre utilisees dans le traitement du myelome multiple |
PL3180005T3 (pl) | 2014-11-19 | 2018-06-29 | Active Biotech Ab | Chinolinokarboksyamidy do stosowania w leczeniu białaczki |
BR112022009192A2 (pt) | 2019-12-19 | 2022-07-26 | Active Biotech Ab | Composição, método para tratar uma doença ocular ou distúrbio ocular, e, uso de um composto |
IL295780A (en) | 2020-03-03 | 2022-10-01 | Active Biotech Ab | Tesquinimov or a pharmaceutically acceptable salt thereof for use in combination therapy |
EP4153576A4 (fr) * | 2020-05-21 | 2024-06-19 | Stemsynergy Therapeutics Inc | Inhibiteurs de notch et leurs utilisations |
JP2023535021A (ja) | 2020-07-23 | 2023-08-15 | イラスマス・ユニバーシティ・メディカル・センター・ロッテルダム | 骨髄増殖性腫瘍における新規治療用標的としてのs100タンパク質 |
CA3204120A1 (fr) | 2021-01-18 | 2022-07-21 | Active Biotech Ab | Tasquinomod ou sel pharmaceutiquement acceptable de celui-ci destine a etre utilise dans le traitement du syndrome myelodysplasique |
AU2022281056A1 (en) | 2021-05-25 | 2023-11-30 | Active Biotech Ab | A plurality of tasquinimod particles and use thereof |
CA3221689A1 (fr) | 2021-07-02 | 2023-01-05 | Hans Wannman | Produit pharmaceutique contenant du tasquinimod et procede d'evaluation de la purete dudit produit |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
GB9108547D0 (en) * | 1991-04-22 | 1991-06-05 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
-
1998
- 1998-04-27 SE SE9801474A patent/SE9801474D0/xx unknown
-
1999
- 1999-04-26 DK DK99947036T patent/DK1073639T3/da active
- 1999-04-26 TR TR2000/03061T patent/TR200003061T2/xx unknown
- 1999-04-26 RU RU2000129672/04A patent/RU2197481C2/ru not_active IP Right Cessation
- 1999-04-26 WO PCT/SE1999/000676 patent/WO1999055678A1/fr active IP Right Grant
- 1999-04-26 PT PT99947036T patent/PT1073639E/pt unknown
- 1999-04-26 IL IL13816099A patent/IL138160A0/xx active IP Right Grant
- 1999-04-26 BR BRPI9909925-0A patent/BR9909925B1/pt not_active IP Right Cessation
- 1999-04-26 ID IDW20002183A patent/ID26277A/id unknown
- 1999-04-26 AT AT99947036T patent/ATE228505T1/de active
- 1999-04-26 OA OA1200000301A patent/OA11547A/en unknown
- 1999-04-26 ES ES99947036T patent/ES2188242T3/es not_active Expired - Lifetime
- 1999-04-26 CA CA002329788A patent/CA2329788C/fr not_active Expired - Fee Related
- 1999-04-26 RS YUP-612/00A patent/RS50029B/sr unknown
- 1999-04-26 KR KR1020007011944A patent/KR100571534B1/ko not_active IP Right Cessation
- 1999-04-26 EP EP99947036A patent/EP1073639B1/fr not_active Expired - Lifetime
- 1999-04-26 HU HU0102084A patent/HU227709B1/hu not_active IP Right Cessation
- 1999-04-26 DE DE69904162T patent/DE69904162T2/de not_active Expired - Lifetime
- 1999-04-26 ME MEP-2000-612A patent/ME00870B/fr unknown
- 1999-04-26 AP APAP/P/2000/001933A patent/AP1293A/en active
- 1999-04-26 PL PL99343420A patent/PL190441B1/pl unknown
- 1999-04-26 EE EEP200000613A patent/EE04275B1/xx unknown
- 1999-04-26 NZ NZ506641A patent/NZ506641A/en not_active IP Right Cessation
- 1999-04-26 UA UA2000085078A patent/UA60354C2/uk unknown
- 1999-04-26 JP JP2000545838A patent/JP4045069B2/ja not_active Expired - Lifetime
- 1999-04-26 CZ CZ20003849A patent/CZ297439B6/cs not_active IP Right Cessation
- 1999-04-26 CN CN99805581A patent/CN1113057C/zh not_active Expired - Fee Related
- 1999-04-26 AU AU43013/99A patent/AU747550B2/en not_active Ceased
-
2000
- 2000-08-30 IL IL138160A patent/IL138160A/en not_active IP Right Cessation
- 2000-08-31 IS IS5615A patent/IS2082B/is unknown
- 2000-09-01 ZA ZA200004601A patent/ZA200004601B/en unknown
- 2000-10-19 NO NO20005254A patent/NO315606B1/no not_active IP Right Cessation
- 2000-10-26 HR HR20000726A patent/HRP20000726B1/xx not_active IP Right Cessation
-
2001
- 2001-08-07 HK HK01105489A patent/HK1036618A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL143782A0 (en) | Quinoline derivatives | |
HK1036618A1 (en) | Quinoline derivatives | |
IL140346A0 (en) | Quinoline derivatives | |
GB9904103D0 (en) | Quinoline derivatives | |
HUP0103634A3 (en) | Quinoline derivatives | |
PL349504A1 (en) | 1,2-annelated quinoline derivatives | |
IL141226A0 (en) | 1h-imidazopyridine derivatives | |
PL345540A1 (en) | Thiobenzimidazole derivatives | |
HU9900120D0 (en) | Benzosulfone derivatives | |
GB9910384D0 (en) | Alpha-ketoamide derivatives | |
EG23802A (en) | 2-Phenylpyran-4-one derivatives | |
GB9827729D0 (en) | Thieno-indole derivatives | |
EG24161A (en) | Carbostyril derivatives | |
EP1061912A4 (fr) | Derives de phenanthrofuran | |
IL139276A0 (en) | Cyclohexenondioxthio chromanoyl derivatives | |
HK1042478A1 (zh) | 2-氧代-2h-喹啉衍生物 | |
GB9904104D0 (en) | Quinoline derivatives | |
GB9904102D0 (en) | Quinoline derivatives | |
GB9904105D0 (en) | Quinoline derivatives | |
GB9816279D0 (en) | Arylthiazolidinedione derivatives | |
SI1051395T1 (sl) | N-hidroksiformamidni derivati |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PF | Patent in force | ||
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20180426 |